Bristol Myers Squibb (CELG-RI) Total Current Liabilities (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Total Current Liabilities of $18.7 billion for Q2 2026, down 32.22% year-over-year from $27.5 billion in Q2 2025, and down 2.6% quarter-over-quarter from $19.2 billion in Q1 2026.
Bristol Myers Squibb (CELG-RI) Total Current Liabilities (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Total Current Liabilities for 18 consecutive years, with $18.7 billion the latest figure, recorded in Q2 2026.
- In Q2 2026, Total Current Liabilities fell 32.22% year-over-year to $18.7 billion; the TTM figure through Jun 2026 stood at $18.7 billion (down 32.22% YoY), while the FY2025 annual figure was $23.4 billion, down 1.5% from the prior year.
- Total Current Liabilities eased to $18.7 billion in Q2 2026 per CELG-RI's latest filing, from $19.2 billion in the prior quarter.
- Across five years, Total Current Liabilities topped out at $28.1 billion in Q3 2025 and bottomed at $18.7 billion in Q2 2026.
- Historically, Total Current Liabilities has averaged $22.6 billion across 5 years, with a median of $22.7 billion in 2022.
- Annual changes were most pronounced in 2024 — Total Current Liabilities soared 35.3% — and 2026, when it tumbled 32.22%.
- Bristol Myers Squibb's Total Current Liabilities stood at $21.9 billion in 2022, then grew by 1.7% to $22.3 billion in 2023, then advanced by 6.79% to $23.8 billion in 2024, then decreased by 1.5% to $23.4 billion in 2025, then fell by 20.32% to $18.7 billion in 2026.
- Business Quant data shows CELG-RI's Total Current Liabilities at $18.7 billion in Q2 2026, $19.2 billion in Q1 2026, and $23.4 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.66 Bn | 632.90 Bn | 17.26 Bn | 54.90 Bn |
| 2 | AbbVie | 469.84 Bn | 463.27 Bn | 12.70 Bn | 41.64 Bn |
| 3 | Merck | 378.23 Bn | 371.09 Bn | 12.21 Bn | 27.73 Bn |
| 4 | Novartis Ag | 303.01 Bn | 295.32 Bn | 11.24 Bn | 31.75 Bn |
| 5 | Astrazeneca | 258.57 Bn | 253.67 Bn | 12.86 Bn | 31.55 Bn |
| 6 | Amgen | 237.36 Bn | 223.37 Bn | 7.24 Bn | 25.50 Bn |
| 7 | Gilead Sciences | 183.27 Bn | 180.09 Bn | 6.22 Bn | 11.02 Bn |
| 8 | Pfizer | 160.74 Bn | 149.04 Bn | 10.94 Bn | 32.65 Bn |
| 9 | Gsk | 105.88 Bn | 101.72 Bn | 8.24 Bn | -28.89 Bn |
| 10 | Bristol Myers Squibb | 208.28 Mn | -10.86 Bn | 9.25 Bn | 18.66 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.66 Bn |
| Mar 31, 2026 | 19.16 Bn |
| Dec 31, 2025 | 23.42 Bn |
| Sep 30, 2025 | 28.14 Bn |
| Jun 30, 2025 | 27.53 Bn |
| Mar 31, 2025 | 24.07 Bn |
| Dec 31, 2024 | 23.77 Bn |
| Sep 30, 2024 | 22.64 Bn |
| Jun 30, 2024 | 23.27 Bn |
| Mar 31, 2024 | 25.82 Bn |
| Dec 31, 2023 | 22.26 Bn |
| Sep 30, 2023 | 23.46 Bn |
| Jun 30, 2023 | 20.15 Bn |
| Mar 31, 2023 | 19.09 Bn |
| Dec 31, 2022 | 21.89 Bn |
| Sep 30, 2022 | 18.93 Bn |
| Jun 30, 2022 | 20.92 Bn |
| Mar 31, 2022 | 22.82 Bn |
| Dec 31, 2021 | 21.87 Bn |
| Sep 30, 2021 | 21.46 Bn |